Drugs / RO5469754
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01620931 | Nov 2011 → Sep 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO5469754 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01620931 ↗ |
| Modality | Monoclonal antibody | “a Humanized Monoclonal Antibody” NCT01620931 ↗ |
| Route | Intravenous | “Following Intravenous or Subcutaneous Administration” NCT01620931 ↗ |
| Route | Subcutaneous | “Following Intravenous or Subcutaneous Administration” NCT01620931 ↗ |